Back to dashboard
CommercialCoverageLow impact

08.01.82c, Anifrolumab-fnia (Saphnelo®)

Independence Blue Cross·Rheumatology·Pharmacy
Effective date
Apr 29, 2026
We identified it
Jun 19, 2026
Days to comply
—

Summary

Policy 08.01.82c for Anifrolumab-fnia (Saphnelo®) has been reissued with an effective date of April 29, 2026. This is a pharmacy policy update for a specialty medication used to treat systemic lupus erythematosus.

Action Required

Action needed
Before April 29, 2026: Review updated policy 08.01.82c for Anifrolumab-fnia (Saphnelo®) at the provided URL to understand any changes to coverage criteria or prior authorization requirements. Update any prior authorization workflows or documentation requirements for this specialty medication as needed.

Related policy hubs